Impressive Response to Double Inhibition of BRAF and MEK in a Patient with Intrahepatic Cholangiocarcinoma with a Mutation in the BRAF Gene
Presented the case of successful application of targeted therapy in a patient with metastatic cholangiocarcinoma resistant to chemotherapy. After the discovery of the BRAF V600E mutation in the tumor, it was prescribed the therapy with dabrafenib, trametinib, panitumumab and irinotecan, which provided significant improvement in the general condition and marked regression of most of the tumor foci. After achieving the maximum response, the patient was transferred to targeted therapy with dabrafenib and trametinib. The effect persisted for 17 months after the start of therapy and continues to this day. The described case demonstrates the potential of an individual approach to the treatment of common malignant tumors based on the data of molecular profiling of tumor tissue.